Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q2 2024 Earnings Conference
Earnings Call Summary | Mineralys Therapeutics(MLYS.US) Q2 2024 Earnings Conference
G&A expenses rose to $5.9 million for Q2 2024, mainly due to higher compensation expenses and professional fees.The following is a summary of the Mineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call Transcript:
以下是Mineralys Therapeutics，Inc. (MLYS) Q2 2024 業績會電話交流摘要：
Financial Performance:
金融業績：
Mineralys Therapeutics reported cash, cash equivalents, and investments totaling $311.1 million at the end of Q2 2024, up from $239 million at the end of 2023.
R&D expenses were $39.3 million for Q2 2024, driven by increased preclinical and clinical costs for lorundrostat trials and the Explore-CKD trial.
G&A expenses rose to $5.9 million for Q2 2024, mainly due to higher compensation expenses and professional fees.
The net loss widened to $41 million in Q2 2024 from $12.1 million in the same quarter of the previous year.
Mineralys Therapeutics 在2024年Q2季度結束的時候，現金、現金等價物和投資總額爲3111萬美元，高於2023年末的2390萬美元。
2024年Q2，研發支出爲3930萬美元，主要由lorundrostat試驗證明以及Explore-CKD試驗證明所需的臨床和臨床前成本增加驅動。
2024年Q2，G&A支出增長至590萬美元，主要是因爲較高的薪酬支出和專業費用。
2024年Q2淨虧損額從上一年同期的1210萬美元擴大至4100萬美元。
Business Progress:
業務進展：
Mineralys is progressing in the development of lorundrostat with key trials in hypertension and CKD underway or planned.
Advance-HTN and Launch-HTN are pivotal trials aimed at demonstrating lorundrostat's efficacy in hypertension. Both trials are progressing, with Advance-HTN enrollment at about 90% and expected data readout in Q1 2025.
The Explore-CKD trial, aimed at assessing lorundrostat in hypertensive patients with CKD, has been amended to improve enrollment, with results anticipated in H1 2025.
Mineralys正在推進lorundrostat的開發，關鍵試驗正在進行中或計劃中，如治療高血壓和CKD的關鍵試驗。
Advance-HTN 和 Launch-HTN是關鍵試驗，旨在證明lorundrostat在治療高血壓方面的療效。兩項試驗都在進行中，Advance-HTN招募率約爲90％，預計數據出爐時間爲2025年Q1。
Explore-CKD試驗旨在評估lorundrostat對CKD患者的高血壓病人的療效，已經進行了修改以提高招募率，預計結果將在2025年上半年公佈。
Opportunities:
機會：
Leveraging the development of lorundrostat in addressing unmet medical needs in hypertension and CKD, especially in patients with resistant hypertension or those on multiple medications.
利用lorundrostat在解決高血壓和CKD等未滿足的醫學需求方面的開發，特別是對抗耐藥性高血壓患者或多種藥物使用患者的需求。
Risks:
風險：
Delays in clinical trial timelines and adjustments, such as the extended timeline for top line data from the Advance-HTN and Explore-CKD trials.
臨床試驗時間表的延誤和調整，例如Advance-HTN和Explore-CKD試驗上線數據的時間表需要延長。
More details: Mineralys Therapeutics IR
更多細節：Mineralys Therapeutics IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
